Kanishk Kumar: Evolving Therapeutic Landscape in Post-Polycythemia Vera Myelofibrosis

Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared a post on LinkedIn:

“Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Insight, 2026

The treatment landscape for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is experiencing remarkable progress, fueled by groundbreaking research and evolving therapeutic approaches.

Industry leaders including Parexel, Constellation Pharmaceuticals, Incyte Corporation, NS Pharma, and Celgene are spearheading the development of novel treatments designed to tackle the significant unmet medical needs associated with this complex condition.

Through their pioneering therapies, these organizations are redefining how PPV-MF is managed, bringing renewed optimism to affected patients.

As scientific exploration continues to advance, these breakthroughs carry the promise of delivering meaningful and sustained improvements in both clinical outcomes and patients’ overall well-being.

DelveInsight’s ‘Post-Polycythemia Vera Myelofibrosis Pipeline Insight, 2026’ delivers an in-depth evaluation of the existing clinical landscape and future growth opportunities within the PPV-MF market.

The report encompasses disease background, treatment protocols, and a thorough pipeline evaluation spanning preclinical through marketed stages.

It features insights into drug mechanisms of action, ongoing clinical investigations, regulatory milestones, and notable developments including partnerships, acquisitions, funding rounds, and special designations.

For novel PPV-MF drug candidates, the pipeline analysis report offers a comprehensive 360 degrees perspective of the therapeutic landscape, categorized by development stage, product type, administration route, molecule type, and mechanism of action.

The pipeline research also addresses commercial opportunities, existing challenges, prospective collaborations, competitive dynamics, and strategic growth approaches.

Highlights from the Post-Polycythemia Vera Myelofibrosis Pipeline Report

• DelveInsight’s PPV-MF pipeline evaluation reveals a dynamic space with over 17 active companies engaged in developing more than 17 pipeline candidates aimed at PPV-MF treatment.
• Prominent PPV-MF companies include Kartos Therapeutics, Inc. , Parexel , Constellation Pharmaceuticals, Incyte , NS Pharma, Inc. , Celgene , Lynk Pharmaceuticals , Imago BioSciences, Inc., Karyopharm Therapeutics Inc., among others, all advancing their lead compounds to enhance the PPV-MF treatment paradigm.
• Notable PPV-MF pipeline candidates at various developmental stages include Navtemadlin, PXS-5505, Pelabresib, Parsaclisib, NS-018, Luspatercept, LNK01002, IMG-7289, Selinexor, and additional therapies.
• In March : Takeda , in collaboration with Protagonist Therapeutics, reported positive Phase III outcomes for rusfertide, which successfully achieved its primary endpoint in a trial enrolling polycythemia vera (PV) patients.

Both companies intend to leverage the Verify trial data to support regulatory submissions for this hepcidin mimetic peptide therapy.

Explore a sample to learn about the latest breakthroughs shaping the PPV-MF pipeline landscape

Post-Polycythemia Vera Myelofibrosis: Disease Background

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is an uncommon, chronic hematologic malignancy that may arise in individuals previously diagnosed with Polycythemia Vera. In this condition, the bone marrow becomes dysfunctional, generating abnormal blood cells and progressively developing fibrotic scar tissue.

PPV-MF ranks among the more frequently encountered intracranial tumor types.

In the United States, annual incidence is estimated at approximately 98,000 to 170,000 cases.

The growing prevalence of PPV-MF is attributed to multiple factors, including extended survival among patients with systemic metastatic disease owing to novel systemic treatments such as immunotherapy.

Furthermore, improvements in high-sensitivity magnetic resonance imaging (MRI) technology have facilitated the identification of smaller, often symptom-free PPV-MF cases.

Discover more about PPV-MF treatment options 

PPV-MF Treatment Analysis: Featured Drug Profiles

Navtemadlin – Kartos Therapeutics, Inc.

Navtemadlin (KRT-232) is an experimental oncology agent that selectively targets and inhibits the MDM2 protein.

In preclinical models and cell-based assays, the compound demonstrated potent MDM2 inhibition at low concentrations and induced dose-dependent p53 activation.

This mechanism triggered cell-cycle arrest via p21 upregulation and subsequent cancer cell death through pro-apoptotic Bcl-2 family members, yielding complete and sustained tumor regression.

Encouraging clinical responses have been documented in patients with advanced malignancies, including Myelofibrosis, Acute Myeloid Leukemia, and Merkel cell carcinoma.

Navtemadlin is presently undergoing Phase II/III evaluation for Post-Polycythemia Vera Myelofibrosis (Post-PV-MF).

Selinexor – Karyopharm Therapeutics Inc.

Selinexor is a pioneering, orally administered Selective Inhibitor of Nuclear Export (SINE) compound. Its mechanism involves binding to and blocking the nuclear export protein XPO1, resulting in the nuclear accumulation of tumor suppressor proteins.

This restores and amplifies their anti-tumor activity, selectively triggering apoptosis in malignant cells while leaving healthy cells unaffected.

Selinexor is currently under Phase II clinical investigation to assess its efficacy and safety profile in myelofibrosis patients (PMF, PET-MF, or PPV-MF) who have shown resistance or intolerance to JAK1/2 inhibitor therapy.

Leading PPV-MF Therapies and Their Developers

• Navtemadlin – Kartos Therapeutics, Inc.
• Selinexor – Karyopharm Therapeutics Inc.
• Pelabresib – Morphosys
• Imetelstat – Geron
• Reblozyl (Luspatercept/ACE-536) – Bristol Myers Squibb
• Navtemadlin (KRT-232) – Kartos Therapeutics

Explore the latest and emerging PPV-MF pipeline therapies

Post-Polycythemia Vera Myelofibrosis Therapeutics Classification

By Product Type

• Monotherapy
• Combination Therapy
• Monotherapy/Combination

By Development Stage

• Late-stage candidates (Phase III)
• Mid-stage candidates (Phase II)
• Early-stage candidates (Phase I), along with details on:

By Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type

• Oligonucleotide
• Peptide
• Small molecule

Report Scope: PPV-MF Pipeline

• Geographic Coverage: Global
• Key PPV-MF Companies: Kartos Therapeutics, Inc. , Parexel , Constellation Pharmaceuticals, Incyte , NS Pharma, Inc. , Celgene , Lynk Pharmaceuticals , Imago BioSciences, Inc., Karyopharm Therapeutics Inc., and others.
• Key PPV-MF Pipeline Candidates: Navtemadlin, PXS-5505, Pelabresib, Parsaclisib, NS-018, Luspatercept, LNK01002, IMG-7289, Selinexor, and others.

Access detailed insights on therapies used in PPV-MF treatment 

Report Structure

1. Introduction
2. Executive Summary
3. PPV-MF Pipeline: Overview
4. Analytical Perspective and In-Depth Commercial Evaluation
5. PPV-MF Pipeline Therapeutics
6. PPV-MF Pipeline: Late-Stage Candidates (Phase III)
7. PPV-MF Pipeline: Late-Stage Candidates (Phase III)
8. PPV-MF Pipeline: Mid-Stage Candidates (Phase II)
9. PPV-MF Pipeline: Early-Stage Candidates (Phase I)
10. Therapeutic Evaluation
11. Inactive Candidates
12. Company-Academic Collaboration (Licensing/Partnership) Analysis
13. Key Companies
14. Key Products
15. Unmet Medical Needs
16. Market Drivers and Barriers
17. Future Outlook and Conclusions
18. Analyst Perspectives
19. Appendix

About DelveInsight

DelveInsight is a premier healthcare-focused market research and consulting firm dedicated to delivering high-quality market intelligence and strategic analysis that supports well-informed business decisions.

Backed by a team of experienced industry specialists with deep expertise across the life sciences and healthcare sectors, DelveInsight offers customized research solutions and actionable insights to organizations worldwide.

Connect with us to access accurate, real-time intelligence that positions you ahead of the growth curve.”

Other articles featuring Kanishk Kumar on Hemostasis Today.